GoodRx Report Shows Millions at Risk as Endocrinologist Shortages Hit Nearly 70% of U.S. Counties
GoodRx (GDRX) has released a critical healthcare report revealing that nearly 70% of U.S. counties lack endocrinologists, affecting approximately 50 million Americans. The study shows people in these 'endocrinology deserts' face a 12% higher mortality rate from endocrine-related diseases.
The shortage particularly impacts diabetes care, with death rates more than doubling in affected areas. For example, Buffalo County, South Dakota reports 143.3 deaths per 100,000 compared to 56.6 in Bell County, Kentucky, where specialists are available.
To address these challenges, GoodRx offers up to 80% savings on diabetes medications, with 20 medications under $20, exclusive brand-name discounts on GLP-1 and GIP medications, and comprehensive healthcare resources through their Diabetes Center.
GoodRx (GDRX) ha pubblicato un importante rapporto sulla salute che rivela che quasi il 70% delle contee statunitensi è privo di endocrinologi, colpendo circa 50 milioni di americani. Lo studio mostra che le persone che si trovano in questi 'deserti endocrinologici' affrontano un tasso di mortalità superiore del 12% dalle malattie legate all'endocrinologia.
La carenza colpisce particolarmente le cure per il diabete, con tassi di mortalità che più che raddoppiano nelle aree interessate. Ad esempio, la Contea di Buffalo, in Dakota del Sud, riporta 143,3 morti ogni 100.000 rispetto a 56,6 nella Contea di Bell, in Kentucky, dove sono disponibili specialisti.
Per affrontare queste problematiche, GoodRx offre sconti fino al 80% sui farmaci per il diabete, con 20 farmaci a meno di $20, sconti esclusivi sui medicinali GLP-1 e GIP di marca, e risorse sanitarie complete attraverso il loro Centro per il Diabete.
GoodRx (GDRX) ha publicado un informe crítico de salud revelando que casi el 70% de los condados de EE.UU. carecen de endocrinólogos, afectando a aproximadamente 50 millones de estadounidenses. El estudio muestra que las personas en estos 'desiertos endocrinológicos' enfrentan un tasa de mortalidad un 12% más alta por enfermedades relacionadas con el sistema endocrino.
La escasez impacta especialmente en el cuidado de la diabetes, con tasas de mortalidad que se duplican en las áreas afectadas. Por ejemplo, el Condado de Buffalo, Dakota del Sur, reporta 143,3 muertes por cada 100,000 en comparación con 56,6 en el Condado de Bell, Kentucky, donde están disponibles especialistas.
Para abordar estos desafíos, GoodRx ofrece hasta 80% de ahorro en medicamentos para la diabetes, con 20 medicamentos a menos de $20, descuentos exclusivos en medicamentos GLP-1 y GIP de marca, y recursos de salud integrales a través de su Centro de Diabetes.
GoodRx (GDRX)는 미국의 거의 70% 카운티가 내분비학자를 결핍하고 있다는 중요한 의료 보고서를 발표했으며, 약 5천만 미국인에게 영향을 미치고 있습니다. 이 연구에 따르면, 이러한 '내분비학의 사막'에 살고 있는 사람들은 내분비 관련 질병으로 인한 사망률이 12% 더 높습니다.
이 부족은 특히 당뇨병 치료에 영향을 미치며, 영향을 받는 지역에서는 사망률이 두 배 이상 증가합니다. 예를 들어, 사우스다코타주 버팔로 카운티는 100,000명당 143.3명이 사망하는 반면, 전문의가 있는 켄터키주 벨 카운티에서는 56.6명이 사망합니다.
이러한 문제를 해결하기 위해 GoodRx는 당뇨병 약품에 대해 최대 80% 절약을 제공하며, 20가지 약품을 20달러 이하로 제공하고, GLP-1 및 GIP 약품에 대한 독점 브랜드 할인과 당뇨병 센터를 통한 종합적인 의료 자원을 제공합니다.
GoodRx (GDRX) a publié un rapport de santé crucial révélant que près de 70 % des comtés américains manquent d'endocrinologues, touchant environ 50 millions d'Américains. L'étude montre que les personnes vivant dans ces 'déserts endocrinologiques' font face à un taux de mortalité supérieur de 12 % en raison de maladies liées à l'endocrinologie.
La pénurie a un impact particulièrement important sur les soins pour le diabète, avec des taux de mortalité plus que doublés dans les zones touchées. Par exemple, le comté de Buffalo dans le Dakota du Sud enregistre 143,3 décès pour 100 000 contre 56,6 dans le comté de Bell dans le Kentucky, où des spécialistes sont disponibles.
Pour faire face à ces défis, GoodRx propose jusqu'à 80 % d'économies sur les médicaments contre le diabète, avec 20 médicaments à moins de 20 dollars, des réductions exclusives sur les médicaments de marque GLP-1 et GIP, et des ressources de santé complètes via leur Centre de Diabète.
GoodRx (GDRX) hat einen wichtigen Gesundheitsbericht veröffentlicht, der zeigt, dass fast 70% der US-Kreise keine Endokrinologen haben, was etwa 50 Millionen Amerikaner betrifft. Die Studie zeigt, dass Menschen in diesen 'endokrinologischen Wüsten' eine 12% höhere Sterblichkeitsrate bei endokrinologischen Erkrankungen aufweisen.
Der Mangel hat insbesondere Auswirkungen auf die Diabetesversorgung, wobei die Sterberaten in betroffenen Gebieten mehr als doppelt so hoch sind. So verzeichnet der Buffalo County in South Dakota 143,3 Todesfälle pro 100.000 im Vergleich zu 56,6 im Bell County, Kentucky, wo Spezialisten verfügbar sind.
Um diesen Herausforderungen zu begegnen, bietet GoodRx Einsparungen von bis zu 80% auf Diabetesmedikamente an, mit 20 Medikamenten unter 20 Dollar, exklusiven Markenrabatten auf GLP-1 und GIP Medikamente sowie umfassenden Gesundheitsressourcen über ihr Diabeteszentrum.
- Offers up to 80% savings on diabetes medications
- Provides access to 20 medications under $20 for diabetes treatment
- Partners with 70,000+ pharmacies nationwide
- Has helped consumers save over $75 billion on prescriptions since 2011
- Trusted by 25 million consumers and 750,000 healthcare professionals annually
- Report reveals critical healthcare access issues affecting company's target market
- Rising medication costs and pharmacy closures creating additional barriers to care
Insights
50 Million Americans Face Critical Gaps in Care as Demand for Endocrinologists Surges
Living in an Endocrinology Desert Increases Mortality Risk by
The findings come at a critical time as the prevalence of diabetes continues to surge nationwide. Over 38 million Americans are living with diabetes, yet many cannot access the specialized care needed to manage their condition effectively. Endocrinologists play a critical role in diagnosing and managing complex hormonal and metabolic conditions, including diabetes, obesity, menopause, thyroid disorders, and more. But for 50 million Americans in endocrinology deserts, help is likely out of reach. The lack of access correlates with significantly higher rates of diabetes complications, obesity, stroke, and even death.
Key findings from the report include:
-
Nearly
70% ofU.S. counties are entirely without an endocrinologist, leaving millions to delay treatment, travel long distances, or go without care altogether. -
People in counties without endocrinologists face a
12% higher mortality rate from endocrine-related diseases, along with elevated rates of diabetes complications, obesity, and stroke. For patients, this could mean more hospital visits, increased medical expenses, and worse health outcomes. -
Diabetes death rates soar in endocrinology deserts, more than doubling in places like
Buffalo County, South Dakota (143.3 per 100,000), compared toBell County, Kentucky (56.6 per 100,000) where specialists are available.
“The shortage of endocrinologists creates a critical barrier to care, leaving millions unable to manage life-altering conditions—a challenge compounded by rising medication costs and pharmacy closures,” said Tori Marsh, MPH, Director of Research at GoodRx. “Addressing these disparities requires innovative, equitable solutions like telemedicine and incentives for specialists to serve underserved areas, ensuring all patients have access to the treatment they need.”
GoodRx is dedicated to supporting people with diabetes by making essential care more accessible through substantial savings on medications and devices like continuous glucose monitors, as well as expert-created health content to empower individuals to make informed health decisions for themselves and their families. Key offerings include:
-
Savings on generic diabetes medications. Save up to
80% off diabetes medications, with 20 medications under to treat diabetes and related conditions.$20 - Exclusive brand-name discounts. Save on commonly prescribed GLP-1 and GIP medications.
- Trusted health resources. Visit the Diabetes Center for expert advice and treatment options written by doctors, pharmacists, and health experts.
The full endocrinology desert report is available from GoodRx Research, here.
About GoodRx
GoodRx is the leading prescription savings platform in the
GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.
GoodRx Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings and accessibility; and the objectives and potential benefits and value of the GoodRx research and savings. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause GoodRx’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to GoodRx’s ability to achieve broad market education and change consumer purchasing habits, changes in medication pricing and pricing structures, GoodRx’s reliance on a limited number of industry participants, and the important factors discussed in the section entitled “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year ended December 31, 2023, and GoodRx’s other filings with the Securities and Exchange Commission. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While GoodRx may elect to update such forward-looking statements at some point in the future, GoodRx disclaims any obligation to do so, even if subsequent events cause GoodRx’s views to change.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241217013913/en/
Media Contact
press@goodrx.com
Source: GoodRx
FAQ
What percentage of U.S. counties lack endocrinologists according to GoodRx's 2024 report?
How much higher is the mortality rate in areas without endocrinologists?
What savings does GDRX offer on diabetes medications?
How many pharmacies are in GoodRx's network as of 2024?
How many consumers and healthcare professionals use GoodRx annually?